Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS‐mediated autophagic cell death in breast cancer

Dysregulation of G6PD involved in the pentose phosphate pathway (PPP) is known to promote tumorigenesis. The PPP plays a pivotal role in meeting the anabolic demands of cancer cells. However, the detailed underlying molecular mechanisms of targeting the G6PD‐regulated PPP in breast cancer remain unclear. In this study, we aimed to elucidate the molecular pathways mediating the effects of G6PD on cancer progression. Clinical sample analysis found that the expression of G6PD in breast cancer patients was higher than that in normal controls, and patients with higher G6PD expression had poor survival. Gene knockdown or inhibition of G6PD by 6‐AN in MCF‐7 and MDA‐MB‐231 cells significantly decreased cell viability, migration, and colony formation ability. G6PD enzyme activity was inhibited by 6‐AN treatment, which caused a transient upregulation of ROS. The elevated ROS was independent of cell apoptosis and thus associated with abnormal activated autophagy. Accumulated ROS levels induced autophagic cell death in breast cancer. Inhibition of G6PD suppresses tumour growth in preclinical models of breast cancer. Our results indicate that targeting the G6PD‐regulated PPP could restrain tumours in vitro and in vivo, inhibiting G6PD caused cell death by over‐activating autophagy, therefore leading to inhibited proliferation and tumour formation.

[1]  J. Koo,et al.  Glucose Metabolism and Glucose Transporters in Breast Cancer , 2021, Frontiers in Cell and Developmental Biology.

[2]  S. Gibson,et al.  Reactive Oxygen Species (ROS) Regulates Different Types of Cell Death by Acting as a Rheostat , 2021, Oxidative medicine and cellular longevity.

[3]  Y. Bao,et al.  TSP50 promotes hepatocyte proliferation and tumour formation by activating glucose‐6‐phosphate dehydrogenase (G6PD) , 2021, Cell proliferation.

[4]  Junjian Wang,et al.  S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis. , 2020, Chemico-biological interactions.

[5]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  Ping Liu,et al.  Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism , 2019, International journal of molecular sciences.

[7]  D. Chiu,et al.  The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer , 2019, Cells.

[8]  M. Caraglia,et al.  Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation , 2019, Journal of Experimental & Clinical Cancer Research.

[9]  R. Parsanathan,et al.  Glucose-6-phosphate dehydrogenase deficiency increases cell adhesion molecules and activates human monocyte-endothelial cell adhesion: Protective role of l-cysteine. , 2019, Archives of biochemistry and biophysics.

[10]  Hong-Sheng Zhang,et al.  Nrf2 promotes breast cancer cell migration via up‐regulation of G6PD/HIF‐1α/Notch1 axis , 2019, Journal of cellular and molecular medicine.

[11]  J. Yao,et al.  ROS-induced autophagy regulates porcine trophectoderm cell apoptosis, proliferation, and differentiation. , 2019, American journal of physiology. Cell physiology.

[12]  T. Akinyemiju,et al.  Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype , 2018, Breast Cancer Research and Treatment.

[13]  Jianhua Wang,et al.  MicroRNA-206 suppresses proliferation and predicts poor prognosis of HR-HPV-positive cervical cancer cells by targeting G6PD , 2018, Oncology letters.

[14]  R. Amaravadi,et al.  Targeting autophagy in cancer , 2018, Cancer.

[15]  Hao Pan,et al.  Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro. , 2018, International journal of oncology.

[16]  M. Miyagishi,et al.  Transcription Factor YY1 Promotes Cell Proliferation by Directly Activating the Pentose Phosphate Pathway. , 2018, Cancer research.

[17]  K. Ghoshal,et al.  The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer , 2018, Scientific Reports.

[18]  M. Caraglia,et al.  A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo , 2018, Cell Death & Disease.

[19]  A. Nadeem,et al.  Glucose‐6‐phosphate dehydrogenase inhibition attenuates acute lung injury through reduction in NADPH oxidase‐derived reactive oxygen species , 2018, Clinical and experimental immunology.

[20]  J. Liu,et al.  Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer , 2017, Oncogene.

[21]  Yuechun Zhu,et al.  Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma , 2017, Journal of Cancer.

[22]  O. Fiehn,et al.  Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. , 2016, Cancer letters.

[23]  Ji‐Won Kim,et al.  Glucose-6-Phosphate Dehydrogenase Deficiency Improves Insulin Resistance With Reduced Adipose Tissue Inflammation in Obesity , 2016, Diabetes.

[24]  Minghui Zhang,et al.  Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma , 2015, World Journal of Surgical Oncology.

[25]  Jianquan Hou,et al.  Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras-TAp73-G6PD axis in bladder cancer cells. , 2015, Molecular medicine reports.

[26]  P. Jiang,et al.  Regulation of the pentose phosphate pathway in cancer , 2014, Protein & Cell.

[27]  I. Martínez-Reyes,et al.  The H(+)-ATP synthase: a gate to ROS-mediated cell death or cell survival. , 2014, Biochimica et biophysica acta.

[28]  J. Blenis,et al.  Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells , 2014, Cell Death and Disease.

[29]  T. Mak,et al.  TAp73 enhances the pentose phosphate pathway and supports cell proliferation , 2013, Nature Cell Biology.

[30]  A. Jordan,et al.  Novel steroid inhibitors of glucose 6-phosphate dehydrogenase. , 2012, Journal of medicinal chemistry.

[31]  Ji‐Won Kim,et al.  G6PD up-regulation promotes pancreatic beta-cell dysfunction. , 2011, Endocrinology.

[32]  J. Loscalzo,et al.  High glucose inhibits glucose‐6‐phosphate dehydrogenase, leading to increased oxidative stress and β‐cell apoptosis , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  J. Loscalzo,et al.  Glucose‐6‐phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  H. Barrach,et al.  Inhibition of NADP dependent oxidoreductases by the 6‐aminonicotinamide analogue of NADP , 1970, FEBS letters.

[35]  Y. Murakumo,et al.  Prognostic significance of G6PD expression and localization in lung adenocarcinoma. , 2019, Biochimica et biophysica acta. Proteins and proteomics.

[36]  R. Mittler.  ROS Are Good. , 2017, Trends in plant science.